The State of Ohio reported its first coronavirus cases on March 9. Prior to that, on February 28, the Cleveland Clinic announced that they are prepared to open 1,000 additional hospital beds if needed. Ohio was one of the states to follow recommendations and intervene quickly.
Ankur Kalra asks Grant W Reed, Director of the Cleveland Clinic’s STEMI program, to reflect on the actions they took and the challenges of delaying cardiovascular procedures in the wake of the coronavirus pandemic. Dr Reed offers insight on the factors that influenced the Cleveland Clinic’s STEMI policy for COVID-19. Ankur and Grant discuss the triage considerations for patients with structural heart disease and the steps the clinic took to protect its healthcare workers.
In this week’s Parallax Dr Kalra and Dr Reed are addressing questions in the wake of Cleveland Clinic’s decision to reopen services for essential procedures. Which cardiac operations should be performed? What is the impact of COVID-19 outbreak on cardiac surgery? How can healthcare institutions address the safety concerns of their patients?
Tune in to listen to this week’s episode of Parallax. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Submit your questions to Ankur via: podcast@radcliffe-group.com.
Related Sources
www.washingtonpost.com/national/heal…88_story.html
In this week’s Parallax, Dr Kanaa’N, the director of the program, and Dr Lahorra, chairman of the Heart, Vascular & Thoracic Department of Akron General introduce the listeners to the foundations of their program and the paradigm shift brought by TAVR.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.